Compare CENT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | STOK |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | CENT | STOK |
|---|---|---|
| Price | $33.03 | $30.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $50.00 | $34.50 |
| AVG Volume (30 Days) | 66.8K | ★ 813.5K |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | N/A |
| EPS | ★ 2.55 | 0.68 |
| Revenue | ★ $3,129,064,000.00 | $205,632,000.00 |
| Revenue This Year | $2.17 | $430.24 |
| Revenue Next Year | $2.13 | N/A |
| P/E Ratio | ★ $12.98 | $44.66 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $28.77 | $5.35 |
| 52 Week High | $41.25 | $38.69 |
| Indicator | CENT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 45.86 |
| Support Level | $31.41 | $25.21 |
| Resistance Level | $32.57 | $37.34 |
| Average True Range (ATR) | 0.60 | 1.89 |
| MACD | 0.05 | -0.41 |
| Stochastic Oscillator | 84.85 | 44.52 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.